



MAY 2024

Shift Pharmaceuticals Selected to Present At 2024 Peripheral Nerve Society Annual Meeting

Shift Pharmaceuticals has been selected to present in the “Late Breaking Research” section of the upcoming annual meeting of the Peripheral Nerve Society in Montreal, CA. Dr. O’Connor will present new data in a presentation entitled “Can Severely De-myelinated Axons be Recovered? Positive Evidence in 12-Month old C3 Mice.” on Thursday, June 25th.

More information can be found at:

<https://pnsociety.com/2024-pns-annual-meeting/>

ABOUT SHIFT PHARMACEUTICALS

Columbia, MO: Shift Pharmaceuticals (a privately held company) is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders. Our first candidate (E1^{v1.11}) targets patients born with Spinal Muscular Atrophy (SMA). SMA occurs in 1:11,000 live births with devastating effects, often proving fatal for most patients under the age of 2. SMA is the leading genetic cause of infantile death worldwide and is marked by severe neurodegeneration and skeletal muscle wasting. Shift was co-founded by serial entrepreneur Dr. Steve O’Connor and world leading SMA research expert Dr. Chris Lorson. The company has licensed the core intellectual property from The University of Missouri, where the initial discovery and development was performed by Dr. Lorson. For more information, visit: www.shiftpharmaceuticals.com.

CONTACT:

Shift Pharmaceuticals

Dr. Steve O’Connor, CEO

(626) 893-2514

steve.oconnor@shiftpharmaceuticals.com